A sponsor will have to demonstrate success with "with several consecutive patients with different bespoke therapies" to ...

The German company developed 177Lu-edotreotide to treat SSTR-positive gastroenteropancreatic neuroendocrine tumors and expects an agency decision in August.

The group recommends considering risk-reducing surgery for those with ovarian cancer risk and enhanced surveillance to manage breast cancer risk.

The firm will use its AI platform to identify biomarkers of response to combination immunotherapy and chemoradiotherapy.

CTX310 showed promising safety and efficacy in a small Phase I trial, according to data presented at the American Heart ...

The Boston-based firm will use the funds to develop its pipeline of optogenetic treatments for neurological disorders, starting with trigeminal pain.

At its annual meeting, the society discussed progress it has made in pushing ahead the Access to Genetic Counselor Services ...

The firm will use the proceeds for gene-editing R&D, working capital, and general corporate purposes, the company said.

The firm has begun dosing extensive-stage small cell and Merkel cell cancer patients with 225Ac-SSO110 in a Phase I/II trial.

Two analyses presented at the National Society of Genetic Counselors' annual meeting indicate the CPT code change has led to an increase in billable hours.

Investigators who designed a base-editing treatment are planning an "umbrella of umbrellas" trial, while others are developing roadmaps to guide personalized treatments.

The drugmaker is paying MeiraGTx $75 million upfront and $400 million in milestone payments to gain access to a treatment for LCA4 caused by AIPL1 mutations.